title: [Safety of Zyban administration in nicotine dependence treatment].
abstract: Zyban (bupropion hydrochloride, produced by Glaxo Wellcome Group) is a drug available in Poland used in a nicotine dependence treatment, as an aid in smoking cessation. The aim of the study was to review available information concerning observed side-effects of Zyban. The information provided by producer, articles and reports published in MEDLINE and EMBASE databases since January 2001 till September 2004 were analysed. Side-effects were analysed, compared and classified according to anatomy-physiological systems, where these side-effects are observed.
authors.affiliation: Katedra Chemii Ogólnej i Analitycznej Slaskiej Akademii Medyczej w Sosnowcu. mgoniewicz@wp.pl
authors.forename: Maciej L
authors.initials: ML
authors.lastname: Goniewicz
authors.forename: Jan
authors.initials: J
authors.lastname: Czogała
mesh_terms: D016642:Bupropion / Q000008:administration & dosage* / Q000009:adverse effects*; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D016540:Smoking Cessation / Q000379:methods; D014029:Tobacco Use Disorder / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018765:Dopamine Uptake Inhibitors; D016642:Bupropion